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Abstract
Closure of persistent foramen ovale (PFO) to avoid cryptogenic strokes is performed globally with enthusiasm but lacks
prove of efficacy. We present a 79-year-old man who had had a PFO device introduced nine years previously because of
cryptogenic strokes presenting as syncopes. The patient was referred from his general practitioner with two new
syncopes. Transthoracic echocardiography revealed no cardiac causes of embolism. Transesophageal echocardiography
(TEE) revealed a misplaced device like an umbrella in a storm, but no septum defects. Holter revealed seconds-long
episodes of atrial fibrillation (AF). The patient was successfully treated with anticoagulation.
A literature review showed that: (i) the efficacy of PFO closure devices has not been proven in any trial, but was
demonstrated in a meta-analysis comparing three different devices; (ii) PFO devices are rarely controlled by TEE during
or after insertion; (iii) residual shunts are detected in up to 45% of cases; (iv) there is an increased rate of post-
arrhythmic complications; (v) the risk of AF in congenital heart disease increases with increasing age, with a 13% risk
of transient ischemic attacks and stroke; and (vi) surgical treatment of PFO was found to have a 4.1% risk of compli-
cations including stroke.
The question to be asked is whether device closure of PFO should be avoided, considering that PFO is a congenital heart
defect with risks of AF and (cryptogenic) stroke? Heart surgery should be a treatment option for symptomatic PFO.
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Introduction
To bypass the maternal oxygenated blood from fetal
lung circulation, the blood passes through the foramen
ovale. The onset of respiration after birth causes an
increase in Qp/Qs, hence pulmonary vascular resistance
decreases, leading to higher left atrial pressures and
closure of the foramen ovale ﬂap against the septum
secundum. The contact between the septum primum
ﬂap and the septum secundum leads to fusion of these
tissues and permanent closure of the foramen ovale
(Fig. 1).
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Transesophageal studies (TEE) reveal that 9–12% of
the general population have a persistent foramen ovale
(PFO) (1), increasing to 29% with catheter probing
during ablation for atrial ﬁbrillation (AF) (2,3).
Autopsy studies reveal that 27% of PFOs have diam-
eters in the range of 1–10mm and that size increases
with age (4); the size of the PFO predicts the risk of
paradoxical embolism (5).
PFO is reported to be the cause of cryptogenic
stroke in 31–77% of cases, while atrial septal aneur-
ysms are the cause in 4–25% of cases (6,7).
Cryptogenic stroke through a PFO was ﬁrst described
in 1877 by Julius Cohnheim during an autopsy of a
young woman with a fatal occlusion of a cerebral
artery. He observed that the patient had a signiﬁcant
lower limb thrombus and a large PFO. He hypothesized
that the latter served as a conduit for an arterial embol-
ism that paradoxically started in the venous circulation.
The Paradoxical Emboli from Large Veins in Ischemic
Stroke (PELVIS) study conﬁrmed that patients with
cryptogenic stroke have an increased prevalence
(20%) of pelvic deep venous thrombosis (8).
Cryptogenic stroke also seems to be associated with
vigorous or strenuous exercise, decompression illness,
sneezing, coughing, obstructive sleep apnea, and even
migraine (9–17).
A transcatheter approach to close the most common
congenital heart defect in adults, ostium secundum
atrial septal defect (ASD), was successfully introduced
in uncomplicated cases four decades ago due to its min-
imally invasive nature compared to open heart surgery
(18,19). Inspired by the success in treating atrial septal
secundum defects, closure of PFO to avoid cryptogenic
stroke and hence transient ischemic attacks (TIA)
(6,20) is performed globally with enthusiasm but lacks
proof of eﬃcacy (21–24).
This case drew our attention to ﬁnd the best evidence
documented treatment of PFO: a 79-year-old man who
had had a PFO device introduced nine years previously,
because of three cryptogenic strokes presenting as syn-
copes, was referred by his general practitioner to our
department with two new syncopes. Initial Holter and
biochemistry were normal (including screening for coa-
gulopathies). Transthoracic echocardiography (TTE)
did not reveal any cardiac causes of embolism. TEE
revealed a misplaced device (Figs. 2–5) like an umbrella
in a storm. Using the method described by Johansson
et al. (25) with prerequisite Valsalva maneuvers before
contrast injections, repeated ﬁve times, we found no
septum defects (Figs. 6 and 7). A second Holter
revealed paroxysmal episodes of AF lasting several sec-
onds. The patient was treated with anticoagulation and
has had no symptoms since. The patient gave verbal
and written consent to the publication of this case
report.
These questions were sought to be answered in the
literature: (i) Is the position of atrial septum devices in
PFO to avoid cryptogenic stroke monitored by TEE
Fig. 1. Interatrial septal development. The primitive atrium is a single cavity (a) subsequently divided by the septum primum which
grows down from the roof of the atrium, toward the developing endocardial cushions (b). Thus, small perforations begin to develop
superiorly resulting in the ostium secundum (c). The atrial roof grows down along the right side of the septum primum, the septum
secundum, which comes to lie over the ostium secundum; however, an opening remains between septa, the PFO (d). At birth, lung
pressures drop and the blood pressure in the left atrium exceeds that of the right atrium, so that the septum primum is shoved against
the septum secundum, obtaining septa fusion (e). If this final step does not occur, PFO results (f). With permission. Courtesy of
Contaldi et al. Cardiovascular Ultrasound 2012;10:16.
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during or after insertion? (ii) What is the complication
rate? (iii) Is insertion of atrial septum devices in PFO to
avoid cryptogenic stroke beneﬁcial compared with
anticoagulation or open heart surgery? (iv) Is the rate
of post-arrhythmic complications known? (v) Is there
an increased risk of AF in patients with PFO?
Methods and Results
To answer the above questions, the following analysis
and a review were performed in MEDLINE and the
Cochrane Collaboration and Cochrane Register of
Controlled Trials for relevant studies. The following
search terms were used: ‘‘PFO’’ AND ‘‘cryptogenic
stroke’’ resulted in 454 articles, while ‘‘PFO’’ AND
‘‘atrial ﬁbrillation’’ resulted in 156 articles, and ‘‘PFO
device’’ AND ‘‘heart surgery’’ resulted in 230 articles.
Searches were not limited, but irrelevant articles and
articles in languages other than English were excluded
(Table 1). The main author performed the literature
search. All studies that appeared to ﬁt the inclusion
criteria were identiﬁed for full review. The retrieved
and selected articles were approved by all authors. Of
those, 92 articles were selected as relevant for the
review.
Discussion
Complication rate and control of the PFO device
position
Atrial septum device misplacements are reported as
rare, but the devices are rarely controlled by TEE
post insertion (26–30). TTE may reveal transient
changes in left atrial passive emptying and strain (31),
while left ventricular function is not aﬀected when
assessed by magnetic resonance imaging (MRI) (32).
However, as in our case, TTE may not reveal displaced
devices or even remaining defects in the PFO.
Fig. 5. 2D transesophageal echocardiography of a displaced
atrial septal occluder (arrow). Test with isotonic solution of
agitated saline water.
Fig. 2. 2D transesophageal echocardiography of a displaced
atrial septal occluder (arrow).
Fig. 3. 3D transesophageal echocardiography of a displaced
atrial septal occluder.
Fig. 4. 3D transesophageal echocardiography of a displaced
atrial septal occluder (arrow).
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Accordingly, a recent follow-up study concluded that
devices evaluated> 5 years after closure with TTE were
well placed (33), but two patients in this population had
their devices surgically removed, and up to 45% had
residual shunting when evaluated with contrast. While
intracardiac ultrasound may be of help during the
insertion of PFO devices (34–39), TEE remains the
diagnostic ‘‘gold standard’’ for evaluating cardioem-
bolic sources of stroke (40–44), and repeated prerequis-
ite Valsalva maneuvers followed by contrast injections
and careful evaluations are important to avoid misin-
terpretations and diagnostic failure (25).
PFO treatment: device closure versus
medical therapy
Jean-Louis Mas et al. (45) reported that patients with
both a patent foramen ovale and an atrial septal aneur-
ysm who had had a cryptogenic stroke had a higher risk
of recurrent stroke while taking aspirin than did
patients with no septal abnormality or either septal
abnormality alone. While overall causes for recurrent
stroke (8%/year) seem equally protected by aspirin
compared to warfarin (46), device closure of PFO has
not yet been proven more eﬀective than medical ther-
apy in preventing recurrent cryptogenic stroke (47–49).
The RESPECT trial, funded by St. Jude Medical,
showed in the primary intention-to-treat analysis that
there was no signiﬁcant beneﬁt associated with closure
of a patent foramen ovale in adults who had had a
cryptogenic stroke, but in pre-speciﬁed per-protocol
and as-treated analyses, device closure was superior to
medical therapy, with a low rate of associated risks
(50); these results from the RESPECT trial were later
conﬁrmed in a sub-analysis excluding patients (who
actually had the device inserted) without indications
for device closure and presented at a conference in
Washington in November 2016, but have not yet been
published. In the CLOSURE I trial, the ﬁrst rando-
mized clinical trial evaluating the eﬀects of PFO closure
on recurrent cryptogenic stroke and TIAs versus med-
ical therapy (51), 909 patients were randomized to per-
cutaneous PFO closure with a STARFlex PFO device
versus medical therapy with warfarin (target inter-
national normalized ratio of 2.0–3.0), aspirin 325mg
alone, or aspirin 81mg plus warfarin. The results did
not demonstrate a beneﬁt of PFO closure with the
STARFlex device compared with medical therapy.
Device closure was successful in only 87% of cases,
which is similar to previous device closure studies
with the STARFlex device (52), but lower than that
reported for other PFO closure devices (53–56). AF and
major vascular complications were signiﬁcantly higher
in the device group, although the latter had no further
implications for the patients, which was conﬁrmed in
other trials (57,58). The population in the CLOSURE I
trial had several atherosclerotic risk factors, including
increased body mass index, diabetes, hypertension, and
Table 1. Literature search strategy.
Citation titles and abstracts 
obtained from litterature search 
(n  =  840)
Excluded: 
Case report (n= 358) 
Conference papers (n=6)  
Duplicate studies (n=1) 
Editorials (n =36)          
Letters (n=39)                 
Notes (n=3)                         
Off Topic (n=66)           
Review articles (n=225)
Short Surveys (n=6) 
Excluded: insufficient data 
(n=8) 
Studies meeting the inclusion 
criteria and analyzed  
in final review  
(n=92) 
Publications retrieved for full study 
review (n=92)
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history of ischemic heart disease predicting recurrent
ischemic neurologic events; however, a diagnosis of
AF after trial enrollment portended the greatest risk
of recurrent events (59).
Each trial on its own failed to signiﬁcantly improve
its primary endpoint in the intention-to-treat analyses.
However, they all point in the same direction: all three
trials were subjects of a recent meta-analysis showing a
signiﬁcant beneﬁt of PFO closure with a> 40% relative
risk reduction for recurrent stroke or TIAs and a 33%
reduction of death or vascular events (60). The beneﬁt
of PFO closure over medical therapy was even
more pronounced when only the trials using the
Amplatzer device were included in the analysis (61).
Also, a single-center study (28) reporting on very
long-term follow-up data on PFO closure or medical
therapy showed signiﬁcantly improved survival (the
most compelling endpoint) in the PFO closure group,
with a relative risk reduction for all-cause mortality
of 60% (P¼ 0.03). Risks of thrombus formation at
the devices seem comparable to other devices, decreas-
ing to negligible after one year (62–64). However,
concluding that device closure is safe by comparing dif-
ferent devices subject to diﬀerent study designs and
analyzing all data in one pool seems too ambitious,
and as explained below, the complications follow-
ing device closure point in another direction.
Percutaneous closure of PFO with the indication
obstructive sleep apnea or migraine also lacks proof
of eﬃcacy (65–68).
Post-arrhythmic complications after device closure
The incidence of AF following device closure is not
reported by Inglessis et al. (69); it is excluded in all
three trials with device closure (60). Interestingly,
Rengifo-Moreno et al. reported a small, but statistically
signiﬁcant increased risk of developing new-onset AF
with the transcatheter closure of PFO when compared
with medical therapy alone (2.7% vs. 0.5%, odds ratio
[OR]¼ 5.7, P< 0.001). In the CLOSURE I trial, it was
associated with signiﬁcantly higher rates of AF than
was medical therapy (5.7% vs. 0.7%; P< 0.001) (51)
and similar results were observed in trials with the
Gore septal occluder, the Intrasept device, and the
Spider PFO occluder (70–72). By contrast, AF
occurred at similar rates after PFO closure with
Amplatzer devices (St. Jude Medical, Plymouth,
MN, USA) compared with medical therapy in the
RESPECT (Randomized Evaluation of Recurrent
Stroke Comparing PFO Closure to Established
Current Standard of Care Treatment) trial (2.9% vs.
1.0%; P¼ 0.16) and in the PC trial (Clinical Trial
Comparing Percutaneous Closure of Patent Foramen
Ovale Using the Amplatzer PFO Occluder with
Medical Treatment in Patients with Cryptogenic
Embolism) (3% vs. 1.5%; P¼ 0.13) (50,73). However,
uniformly comparable heart rhythm monitoring before
device closure was not available in any of the studies,
and recent follow-up studies of ‘‘atrial septum
defects closed with devices’’ demonstrate a high risk
(6.6–17.9%) of AF in the ﬁrst year after the procedure,
decreasing to negligible (0–3.9%), but with only
76–82% of the original population included in one
study (33,74,75).
The risk of AF in patients with PFO and other
congenital heart diseases
AF, which occurs in 1–2% of the general population
and is probably underestimated with an expected dou-
bling in the coming decades, confers a ﬁvefold risk of
stroke and one in ﬁve of all strokes is attributed to this
arrhythmia (76). The AF detection rate with 12-lead
ECG or 24-h Holter is in the range of 2–6% after ische-
mic stroke or transient ischemic stroke (77,78).
However, the CRYSTAL-AF (CRYptogenic STroke
And underLying AF) trial conducted in Europe,
Canada, and the United States used an insertable car-
diac monitor (ICM) from Medtronic (REVEAL XT)
and the EMBRACE study (30-Day Cardiac Event
Monitor Belt for Recording AF After a Cerebral
Ischemic Event) in Canada investigated a non-invasive,
30-day event-triggered loop recorder from Braemar
(ER910AF Cardiac Event Monitor) (79,80) to show
that up to 36 months of heart rhythm monitoring
increased the detection rate of AF from 8.9% after
six months to 12.4% after 12 months and up to
30.0% after 36 months. The aforementioned results
conﬁrm the ﬁndings of observational studies that had
demonstrated a high rate of undetected AF in patients
after cryptogenic stroke (81).
PFO is considered to be a structural (congenital)
heart disease (82) and as a result of structural heart
disease, atrial arrhythmias increase with increasing
age to up to 38% in 50-year-old patients. Yet, these
numbers do not allow the exclusion of the risk asso-
ciated with corrective or palliative surgical procedures
(83,84). Catheter ablation for paroxysmal AF with co-
existing PFO may increase procedure time, while suc-
cess seems to be unaﬀected (2,3). Surgical correction of
PFO, even with minimally invasive (robotic) surgery, is
successful with a low risk of residual shunting or any
other complications and with a lower recurrence of
stroke compared with device closure and is considered
to be the gold standard (85–90) in smaller studies: after
a mean follow-up time of 24 months, only eight patients
(all in one of the four studies) of a total of 194 were
reported to have a TIA as a complication of the direct
suture closure of PFO (Table 3). This is equivalent to
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a total risk of 4.1% and hence considerably lower than
with device closure of PFO.
A recent retrospective longitudinal multicenter study
of 199 patients, ‘‘DysrhythmiAs in patieNts with
congenitAl heaRt diseAse’’ (DaNaRA), demonstrated
that patients with congenital heart disease, particularly
patients with complex defects, develop AF at a young
age and progress frequently from paroxysmal AF to
(long-standing) persistent/permanent AF (91). Sixteen
patients (8%) experienced a cerebrovascular event 14
(2–33) years before the ﬁrst documented AF. The
total incidence of TIA/stroke in the population was
13%. Coexistence of episodes of AF and regular
atrial tachycardia occurred in a considerable number
of patients in this study; most of them initially pre-
sented with regular atrial tachycardia, hence the
authors suggest that aggressive therapy and close
follow-up of congenital heart disease patients with
atrial tachyarrhythmia is justiﬁed (91). A large retro-
spective study comparing the general Danish popula-
tion to> 4400 patients (age range ¼ 1–49 years) with
almost ﬁve decades of follow-up (92) demonstrated
that: (i) AF is more prevalent in patients with ASD
diagnosed and closed in childhood, with a cumulative
incidence of 9.8% at the end of 50 years of follow-up;
and (ii) the risk of arrhythmia is independent of
whether the ASD was closed by catheter or surgery.
Yet the authors of this important study ask: does
closure of an ASD at a young age reduce AF later
in life (92)?
In conclusion, PFO is a common heart defect asso-
ciated with stroke that has been treated for decades
with device closure, although the eﬃcacy has never
been proven. Device closure of PFO is associated
with a high risk of remaining defects, including dis-
placement, and an undetermined increased risk of
AF; the latter may even be the natural cause of so-
called cryptogenic strokes.
We interpret our review of the literature as follows
(Table 2): (i) the eﬃcacy of PFO closure devices has not
been proven in any trial (however, eﬃcacy was proven
in a meta-analysis comparing three diﬀerent devices);
(ii) PFO device positions are rarely controlled by TEE
during or after insertion; (iii) residual shunts can be
demonstrated in up to 45% of cases; (iv) there is an
increased rate of post-arrhythmic complications, espe-
cially AF, which was recently concluded to be an
underdiagnosed and hence increasingly important
cause of cryptogenic strokes; (v) the risk of AF in con-
genital heart disease (which PFO should be considered
to be) increases with increasing age, with a 13% risk of
TIAs and stroke; and (vi) surgery, both minimally inva-
sive and open heart, is a proven treatment of congenital
heart defects causing AF, with a 4.1% risk of
complications.
The question to be asked is whether device closure of
PFO should be avoided, considering that PFO is a con-
genital heart defect with the associated risks of AF and
(cryptogenic) stroke? Heart surgery should be a treat-
ment option for symptomatic PFO.
Table 2. Key points in the review.
Key point Conclusion/review of literature References
Is insertion of atrial septum devices in PFO
to avoid cryptogenic stroke beneficial
compared to anticoagulation or open
heart surgery?
The efficacy of PFO closure devices has not been
proven in any published trial
(21–24,26,36–49,73–78)
Is the position controlled with TEE before
or after insertion?
The positions are rarely controlled with TEE
before or after insertion
(26–27,30–33)
What is the complication rate? Residual shunts can be demonstrated in up to
45% of cases
(30–33,41–44)
Is the rate of post-arrhythmic
complications known?
The rate of post-arrhythmic complications
increases, especially AF, recently concluded as
an underdiagnosed and hence increasingly
important cause of cryptogenic strokes
(30,40,41,58–60,62,63)
Is the risk of AF in patients with PFO
increased?
(Considering PFO as a congenital heart disease)
the risk of AF in congenital heart disease is
increasing with increasing age, with a 13% risk
of TIAs and stroke
(65–72)
How should we treat patients with
cryptogenic stroke and PFO?
Literature points towards surgery as evident
treatment of congenital heart defects including
PFO causing AF
(2,3,36–49,73–80)
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